Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ck is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.

During the first half of 2013 the Company will be having discussions with regulatory authorities regarding future clinical development plans for ibrutinib's use in patients with DLBCL. The Company expects to be able to provide further updates in the third quarter of 2013.

Conference Call and further Corporate UpdatesThe Company will hold a conference call today at 4:30 p.m. EST. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction w
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... dental biomaterial market will grow moderately through 2023 ... procedures and growing awareness of dental biomaterials all spur ... markets such as China and ... will bring dental procedures within reach for a larger ...
(Date:12/17/2014)... NY (PRWEB) December 16, 2014 The ... changes since 2013, which is why IBISWorld updated its ... industry continues to benefit from an intensified focus on ... proposal for new emission standards for power plants and ... operators. According to IBISWorld Industry Analyst Sarah Kahn, “a ...
(Date:12/17/2014)... RIDGE, N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today ... mg (referred to as Somatuline®) was approved by ... the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in ... locally advanced or metastatic disease to improve progression-free ...
(Date:12/17/2014)... Park, CA (PRWEB) December 17, 2014 ... announces today that it has entered into a ... Midland Company (ADM) to apply DNA2.0’s proprietary protein ... enzyme engineering process. , “We are extremely excited ... ProteinGPS engineering platform. This proprietary bioengineering technology ...
Breaking Biology Technology:Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2
... stock held by American Red Cross, in a ... in PRDT to 77%, - American Red Cross to ... MONTREAL and CAMBRIDGE, England, April 9 /PRNewswire-FirstCall/ -,ProMetic ... a Letter of Intent ("LOI") to acquire the American ...
... April 9 Francis S. Collins, M.D., ... Genome Project, has been named,recipient of the ... Center for Ethics and Excellence at Case ... ), The Inamori Ethics Prize honors ...
... Genetic Engineering,and Biotechnology News (GEN), http://www.genengnews.com ... on New Polymeric Drug Delivery Systems, on,Thursday, April ... is institute professor, chemical and biomedical engineering,Massachusetts Institute ... innovator in modern drug delivery," says John Sterling,Editor-in-Chief ...
Cached Biology Technology:ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 2ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 3ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 4ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 5ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 6ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc. 7Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 2Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 3Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University 4Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems 2
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... (Tuesday, April 1, 2008) Identifying genes that ... mouse used to be a monumental task. New ... effective for even the smallest laboratories. This months ... www.cshprotocols.org/TOCs/toc4_08.dtl ) highlights a method for screening the mouse ...
... be the cruelest month? , ... reminiscent of 1993 and 1994, back-to-back years of serious flooding, with ... damage, damaging and destroying more than 50,000 homes and killing at ... Parallels this year include abnormally high levels of precipitation ...
... Like sentinels at their posts, an array of buoys ... on duty in the Stellwagen Bank National Marine Sanctuary ... months, recording sounds from whales, fish, ships and other ... will analyze the biological sounds to help develop a ...
Cached Biology News:Cold Spring Harbor Protocols features methods to screen genomes and analyze evolution 2Geologist decries floodplain development 2Geologist decries floodplain development 3Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 2Researchers to develop ocean sanctuary 'noise budget' to evaluate potential impact on marine mammals 3
Human TFPI Affinity Purified Polyclonal Ab Protein Family: Coagulation, Inflammation, Serine Protease Regulators...
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Eppendorf tube holder, for Tube rack 175 x 12 mm, 100. Category: Chromatography Systems & Accessories, Systems....
Biology Products: